Objective: Tumor protein p53 gene and its negative regulator, murine double minute 2 homolog are important components for cell-cycle arrest and apoptosis. An arginine-to-proline substitution at codon 72 in the p53 gene is reported to decrease apoptotic potential, while a thymine-to-guanine polymorphism at nucleotide 309, named SNP309, of murine double minute 2 gene increases transcription of the gene. These two polymorphisms therefore may be of importance in colorectal carcinogenesis. The relation of these polymorphisms to colorectal cancer risk was addressed in the Fukuoka Colorectal Cancer Study. Methods: We genotyped the two polymorphisms in 685 incident cases of colorectal cancer and 778 community controls by the polymerase chain reaction -restriction fragment length polymorphism method. Statistical adjustment was made for sex and age. Results: The proline allele of p53 gene and the guanine allele of SNP309 were each associated with a small, statistically non-significant increase in the odds ratio of colorectal cancer; the adjusted odds ratio (95% confidence interval) for arginine/proline and proline/proline genotypes combined versus arginine/arginine genotype of p53 gene was 1.23 (0.99 -1.52) and that for thymine/guanine and guanine/guanine genotypes combined versus thymine/thymine genotype of SNP309 was 1.27 (0.98 -1.63). Individuals harboring the proline allele of p53 gene and the guanine allele of SNP309 showed an odds ratio of 1.67 (95% confidence interval, 1.11-2.51). Conclusions: Codon 72 polymorphism of p53 and SNP309 in combination may confer an increased risk of colorectal cancer.
INTRODUCTION
The tumor suppressor p53 plays a critical role in the defense against cancer development and progression. In response to cellular stressors such as DNA damage and oncogene activation, p53 regulates the transcription of a wide range of genes including those involved in cell cycle, apoptosis, inhibition of angiogenesis and cellular senescence (1) . Of known polymorphisms of the encoding gene TP53, the R72P polymorphism (G . C change at nucleotide 215, rs1042522) has drawn much interest in relation to cancer susceptibility and prognosis (1) . In vitro studies suggest that the 72R allele is of greater apoptotic potential, but the role of this polymorphism in the development of human cancers remains uncertain. Regarding the relation between the TP53 R72P polymorphism and colorectal cancer risk, an increased risk associated with the 72P allele was reported in some studies (2 -5), but not in other studies (6 -15) .
The human homolog of the mouse double minute 2 (MDM2) is a core negative regulator of p53 (16) . Bond and colleagues reported a functional polymorphism in the MDM2 promoter region, referred to as SNP309 (a T to G change at the 309th nucleotide in the first intron, rs2279744), showing a greater affinity of the transcription factor Sp1 and a higher expression of mRNA and protein of MDM2 in the GG genotype when compared with the TT genotype in cell lines (16) . The SNP309 G allele was associated with an earlier age of onset of cancer in family members with the Li-Fraumeni syndrome with germline p53 mutations (16 -18) , whereas another study showed that the SNP309 G allele was associated with an earlier age of diagnosis of colorectal cancer in patients with p53 mutationnegative colorectal cancer, but not in those with p53 mutation-positive colorectal cancer (19) . In a combined analysis of five studies with 1620 cases of sporadic and hereditary colorectal cancers combined and 886 controls of diverse sources, the SNP309 GG genotype was unrelated to colorectal cancer risk (20) . Few studies have addressed the combined effect of SNP309 and TP53 R72P polymorphisms on cancer risk. SNP309 was unrelated to risks of breast cancer (21) and bladder cancer (22) singly or in combination with the TP53 R72P polymorphism. One small study of Lynch syndrome patients found no combined effect of SNP309 and TP53 R72P polymorphisms on either the risk of colorectal cancer or age of diagnosis (23) . In the study reported here, we examined the relation of SNP309 and TP53 R72P polymorphisms to the colorectal cancer risk in the Fukuoka Colorectal Cancer Study, Japan.
PATIENTS AND METHODS
The Fukuoka Colorectal Cancer Study is a community-based case -control study of colorectal cancer among Japanese residents living in Fukuoka City and three adjacent areas. The study protocol was approved by the ethics committees of the Kyushu University Faculty of Medical Sciences and the participating hospitals except two, in which no ethics committee existed and the survey was conducted with the approval of each hospital director. Details of the methods have been described elsewhere (24) .
PARTICIPANTS
The cases were a consecutive series of patients with histologically confirmed incident colorectal adenocarcinomas who were admitted to two university hospitals and six affiliated hospitals for surgical treatment from September 2000 to December 2003. Eligible cases were aged 20 -74 years at the time of diagnosis; lived in the study area; had no prior history of partial or total removal of the colorectum, familial adenomatous polyposis or inflammatory bowel disease and were mentally competent to give informed consent and to complete the interview. Research nurses visited each hospital weekly and determined the eligibility of cases by referring to admission logs and medical records. Of the total 1053 eligible cases, 840 cases (80%) participated in the interview and 685 gave informed consent for the genotyping.
Controls were randomly selected from the community by frequency-matching with respect to sex and 10-year age classes. A total of 1500 persons living in 15 geographical areas were selected as control candidates by two-stage random sampling, and were invited to participate in the study by mail. Eligibility criteria for controls were the same as described for the cases except that they had no prior diagnosis of colorectal cancer. The mail invitation revealed that 113 persons were ineligible. In addition, five persons were diagnosed with colorectal cancer after the interview survey. After exclusion of these 118 persons, 833 (60%) of the 1382 eligible candidates participated in the interview, and 778 gave informed consent for genotyping.
Menopausal status as well as lifestyle factors was ascertained by in-person interview. Females aged 54 years or younger with a history of hysterectomy and those who had been in the menopausal status for ,3 years were classified as premenopausal.
GENOTYPING
DNA was extracted from buffy coat using a commercial kit (QIAGEN, Hilden, Germany). Genotyping was performed using the polymerase chain reaction (PCR) -restriction fragment length polymorphism (RFLP) method, with the digested PCR products applied to electrophoresis on agarose gels, and visualized by ethidium bromide. The PCR was performed in a reaction mixture of 10 ml containing 0.5 IU of Taq, and 10 ng of template DNA. The TP53 R72P polymorphism was determined as described previously (25), using primers 5 0 -TTG CCG TCC CAA GCA ATG GAT GA-3 0 (forward) and 5 0 -TCT GGG AAG GGA CAG AAG ATG AC-3 0 (reverse). Restriction enzyme BstUI digested the 199 bp PCR-product into two fragments of 113 and 86 bp for the 72R allele. Genotyping for the SNP309 polymorphism was determined according to the methods described elsewhere (26), using primers 5 0 -CGG GAG TTC AGG GTA AAG GT-3 0 (forward) and 5 0 -AGC AAG TCG GTG CTT ACC TG-3 0 (reverse). The PCR product of 352 bp was digested with MspA1I, resulting in fragments of 187, 88, 46 and 31 bp for the G allele, and 233, 88 and 31 bp for the T allele. After the completion of genotyping in the whole study subjects, 90 subjects were randomly selected for each polymorphism with 30 subjects for each genotype.
Genotypes in the repeat sample were in complete agreement with those in the first assay regarding the two polymorphisms.
STATISTICAL ANALYSIS
Logistic regression analysis was used to estimate the odds ratio (OR) and the 95% confidence interval (CI) for the association between genetic polymorphisms and colorectal cancer. The trend of the association with an increasing number of the variant alleles was assessed by using an ordinal variable for a polymorphism. Statistical adjustment was made for sex and age (continuous variable). Deviation from the Hardy -Weinberg equilibrium was evaluated by x 2 with one degree of freedom. The interaction between the two polymorphisms was evaluated using the likelihood ratio test comparing the models with and without the interaction term. The Kruskal Wallis test was applied to the comparison of medians ages of onset according to genotypes. Statistical significance was declared if the two-sided P value was ,0.05. Statistical analyses were carried out using SAS version 9.2 (SAS Institute, Cary, NC, USA), except for the analyses on the Hardy-Weinberg equilibrium which were performed by using Stata version 10 (StataCorp, College Station, TX, USA).
RESULTS
The median age of onset of colorectal cancer in the cases was 61 years (range 27 -74 years), and the age at interview in controls was 60 years (range 22 -75 years). Males numbered 426 (62.2%) in the cases and 490 (63.0%) in the controls. The frequencies of the TP53 72P allele and the SNP309 G allele in the control groups were 37 and 53%, respectively. Genotype distributions of the TP53 R72P and SNP309 polymorphisms in the controls did not deviate from the Hardy -Weinberg equilibrium (P ¼ 0.77 and P ¼ 0.91, respectively). Table 1 shows the association between the TP53 polymorphism and colorectal cancer risk. In both sexes combined, the OR for the 72RP and 72PP genotype each when compared with the 72RR genotype were slightly greater than unity without statistical significance. When the analysis was done for men and women separately, statistically significant increases in the OR were observed in men with the 72PP genotype and in men carrying the 72P allele. Women showed no association between the TP53 polymorphism and colorectal cancer.
With regards to SNP309 (Table 2) , the OR associated with the G allele was slightly, but statistically nonsignificantly, increased in both sexes combined. Men showed 234 TP53 R72P and MDM2 SNP309 and colorectal cancer a statistically significant increase in the OR of colorectal cancer associated with the G allele, whereas no such increase was observed in women.
In the analysis on the combination of the two polymorphisms (Table 3) , the TP53 72RP and 72PP genotypes as well as the SNP309 TG and GG genotypes were combined. A moderate, statistically significant increase in the OR was observed among individuals with both the TP53 72P and SNP309 G alleles in both sexes combined. An increase in the OR associated with a combination of these two alleles was observed in men, but not in women.
The analysis was repeated for women with stratification by menopausal status. Premenopausal women numbered 172 (81 cases and 91 controls), and post-menopausal women numbered 375 (178 cases and 197 controls). Neither premenopausal nor post-menopausal women showed a clear association of TP53 R72P, SNP309 or the combination of the two polymorphisms with colorectal cancer risk. Adjusted OR for premenopausal women having the TP53 72P allele, SNP309 G allele and their combination when compared with homozygotes of the wild allele each were 0.97 (95% CI, 0.52-1.81), 0.70 (95% CI, 0.34 -1.44) and 0.74 (95% CI, 0.25 -2.24), respectively. The corresponding values for post-menopausal women were 1.09 (95% CI, 0.71-1.66), 1.31 (95% CI, 0.78-2.17) and 1.54 (95% CI, 0.63-3.74), respectively.
We further examined associations with the two polymorphisms singly and in combination in relation to subsitespecific colorectal cancer. Numbers of cases with proximal colon cancer, distal colon cancer and rectal cancer were 150, 232 and 190, respectively. The remaining 13 cases had multiple cancers at different segments. The associations did not appreciably differ by site of the colorectum for the TP53 R72P and SNP309 polymorphisms singly or in combination. For example, adjusted OR for both sexes having both TP53 72P and SNP309 G alleles compared with those homozygous for the TP53 72R and SNP309 T alleles were 2.15 (95% CI, 0.95 -4.89) for proximal colon cancer, 1.66 (95% CI, 0.92 -3.00) for distal colon cancer and 1.62 (95% CI, 0.94 -2.82) for rectal cancer.
The age at onset of colorectal cancer did not differ according to genotypes of SNP309. Median ages for the TT, TG and GG genotypes among men were 63.0, 62.0 and 60.0 years, respectively (P ¼ 0.20). Those for post-menopausal women were 65, 65 and 64 years, respectively (P ¼ 0.96), whereas the corresponding values for premenopausal women were 50, 50 and 51 years (P ¼ 0.23). Jpn J Clin Oncol 2011;41(2) 235
DISCUSSION
The TP53 72P and SNP309 G alleles were each associated with a small, statistically non-significant increase in colorectal cancer risk. Individuals with both of these alleles showed a moderate, statistically significant increase in the risk in both sexes combined. Associations with the SNP309 G allele and the TP53 72P allele, singly or in combination, did not differ by subsite of the colorectum. The association between the TP53 R72P polymorphism and colorectal cancer risk has been inconsistent (2 -15). All of these studies except for one (12) examined the association in both sexes combined. In the study investigating the sexspecific association (12), the TP53 R72P polymorphism was not related to colorectal cancer risk in either men or women. At least five case -control studies have examined the relation between SNP309 and the risk of sporadic or hereditary colorectal cancer in both sexes combined (19,23,27 -29) . These studies failed to find a measurable association between the SNP309 G allele and colorectal cancer risk, while one of these studies suggested an increased risk of colorectal cancer associated with the SNP309 G allele (28) . The present finding on SNP309 is compatible with the previous observation. An increased risk of colorectal cancer for the combination of the TP53 72P and SNP309 G alleles has not been reported previously, and replication of the present findings is needed.
In the present study, increased risks of colorectal cancer associated with the TP53 72P and SNP309 G alleles were not clear in women. We have no immediate biological explanation for a possible sex-difference in the association with the SNP309 as well as with the TP53 R72P polymorphisms. The findings may have been due to chance in the subgroup analysis.
The estrogen-signaling pathway has been implicated in the role of SNP309 in accelerated formation of several cancers (30) . A previous study showed that the SNP309 G allele was associated with an earlier age at the diagnosis of colorectal cancer in women, but not in men (31) . Furthermore, in colorectal cancer cases, the SNP309 G allele was more frequent in premenopausal women than post-menopausal women and men (31) . In the present study, the age at onset of colorectal cancer did not differ by either sex or the menopausal status in women. This finding, together with the null association between SNP309 and colorectal cancer risk in women regardless of the menopausal status, does not support an earlier observation regarding the SNP309 G allele and colorectal cancer development (31) .
Since different molecular alterations have been implicated in carcinogenesis of proximal and distal sites of the colorectum, the site-specific association with the SNP309 and the TP53 R72P polymorphisms was of interest. Two distinct genetic pathways have been proposed in the development of colorectal cancer, i.e. chromosomal instability and microsatellite instability (32) . Chromosomal instability is more frequent in distal colorectal cancer, whereas microsatellite 236 TP53 R72P and MDM2 SNP309 and colorectal cancer instability predominates in proximal cancer (32) . Previously, three studies examined the association of the TP53 R72P polymorphism with site-specific risk of colorectal cancer. One study showed an increased risk associated with the TP53 72P variant allele for proximal colon cancer in women and for distal colon cancer in men (12), whereas another study found an increased risk of left-sided colorectal cancer in individuals homozygous for the TP53 72R allele (13) . The third study found no differential association with the TP53 R72P polymorphism (6) . None has addressed the effect of the SNP309 polymorphism on site-specific risk of colorectal cancer. The present study did not indicate any site-specific associations with either TP53 R72P or SNP309. Genome-wide association studies have recently identified several loci and specific polymorphisms associated with colorectal cancer in Caucasians, as reviewed elsewhere (33, 34) . These loci were, however, not located in chromosomes in which the TP53 R72P and SNP309 polymorphisms are located.
Frequencies of the TP53 72P and SNP309 G alleles in the controls of the present study were 37 and 53%, respectively. The frequency of the TP53 R72P polymorphism varies with ethnicity (35) . The previously reported frequencies of the TP53 72P allele were 35% in Japanese (10), 37% in Koreans (5), 40% in Chinese (4) and 26% in Caucasians (12) . The SNP309 G allele is fairly common in Asian populations, with average frequencies of 49% in Japanese, 53% in Koreans and 48% in Chinese, whereas the frequency is much lower in Caucasians (37%) and African Americans (11%) (20) .
Use of community controls was an advantage in the present study. The largest previous studies that investigated the TP53 R72P or SNP309 polymorphism in relation to colorectal cancer risk were a study on TP53 R72P with 442 cases of colorectal cancer and 904 controls in the USA (12) and a study of 969 cases and 185 healthy controls regarding SNP309 in Finland (27) . Thus, the present study was among the largest ones regarding the TP53 R72P or SNP309 polymorphism and colorectal cancer, but the size was admittedly far less than those of genome-wide association studies. A weakness in the present study was that the participation rate in terms of the genotyping was not high in the cases (65%) and controls (56%). However, it is unlikely that selection bias occurred because the participation probably was not influenced by the TP53 R72P or SNP309 polymorphism. The allele frequencies of these polymorphisms in the present controls were very similar to those reported elsewhere in Japan, as discussed above.
In conclusion, a case -control study in Japan showed that the combination of the TP53 72P and SNP309 G alleles was associated with a moderately increased risk of colorectal cancer.
